Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 8/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102331 | 0.69 | PDPK1 (0.59) | HSP90AA1RAB9APDPK1LOXL2CYP2A6 | |
| SCHEMBL1199404 | 0.68 | CYP19A1 (0.32) | — | |
| SCHEMBL28154527 | 0.67 | PDPK1 (0.56) | HSP90AA1RAB9APDPK1LOXL2CYP2A6 | |
| SCHEMBL31556353 | 0.67 | PDPK1 (0.56) | HSP90AA1RAB9APDPK1LOXL2CYP2A6 | |
| SCHEMBL30534095 | 0.67 | PDPK1 (0.56) | HSP90AA1RAB9APDPK1LOXL2CYP2A6 | |
| SCHEMBL30632310 | 0.67 | PDPK1 (0.56) | HSP90AA1RAB9APDPK1LOXL2CYP2A6 | |
| SCHEMBL30511083 | 0.67 | — | — | |
| SCHEMBL1520398 | 0.67 | HSP90AA1 (0.44) | HSP90AA1RAB9APDPK1SPHK2SPHK1 | |
| SCHEMBL1559449 | 0.67 | HSP90AA1 (0.41) | HSP90AA1RAB9APDPK1SPHK2SPHK1 | |
| SCHEMBL292280 | 0.67 | HSP90AA1 (0.49) | HSP90AA1RAB9APDPK1SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781512-B1 | OXADIAZOLE COMPOUND AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | UNIV SHANGHAI JIAOTONG (CN) | 2017-06-28 | — | — | EP | claimed |
| US-20070060618-A1 | Alkyne derivatives as tracers for metabotropic glutamate receptor binding | MERCK & CO., INC. (US) | 2007-03-15 | — | — | US | claimed |
| CN-1170813-C | N2 phenylamidine derivatives | �ݶ�ũ������˾ | 2004-10-13 | — | — | CN | claimed |
| EP-1054886-B1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-09-04 | — | — | EP | claimed |
| US-20220002294-A1 | ERK INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-06 | — | — | US | disclosed |
| US-8952176-B2 | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8354446-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| CN-102803264-A | 3-substituted-8-substituted-3h imidazo[5,1-d][1,2,3,5-tetrazin-4-one compounds and their use | PHARMINOX LTD | 2012-11-28 | — | — | CN | disclosed |
| EP-2445915-A1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | Pharminox Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120064022-A1 | CYCLOSILOXANE-SUBSTITUTED POLYSILOXANE COMPOUNDS, COMPOSITIONS CONTAINING THE COMPOUNDS AND METHODS OF USE THEREOF | BIOFILM, INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120004220-A9 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2012-01-05 | — | — | US | disclosed |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-5410052-A | Useful for extraction of ligand such as molecular oxygen from fluid environment and for release of such ligand | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-25 | — | — | US | disclosed |
| US-5321000-A | Benzhydryl compounds as herbicide antidotes | MONSANTO COMPANY (US) | 1994-06-14 | — | — | US | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| EP-0318860-B1 | SUBSTITUTED ALKYLAMINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-06-16 | — | — | EP | disclosed |
| US-5162537-A | To safen acetamide herbicids used to control grassy and broadleaf weeds in rice, sorghum and wheat | MONSANTO COMPANY (US) | 1992-11-10 | — | — | US | disclosed |
| US-4964893-A | REDUCING INJURY TO A CROP PLANT | MONSANTO COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| US-4959135-A | OXYGEN | AQUANAUTICS CORPORATION (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0318860-A2 | Substituted alkylamine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SCN1A, SCN2A, CACNA1A | HSP90AA1 1091/4885RAB9A 3195/4885PDPK1 4283/4885 |
| US-20220002294-A1 | ERK INHIBITORS AND USES THEREOF | MAPKAPK2, MAPK3, MAP4K2 | HSP90AA1 1029/4885RAB9A 1501/4885PDPK1 112/4885 |
| US-20120064022-A1 | CYCLOSILOXANE-SUBSTITUTED POLYSILOXANE COMPOUNDS, COMPOSITIONS CONTAINING THE COMPOUNDS AND METHODS OF USE THEREOF | PIEZO1, DSC1, PFAS | HSP90AA1 2777/4885RAB9A 3503/4885PDPK1 3600/4885 |
| US-20070060618-A1 | Alkyne derivatives as tracers for metabotropic glutamate receptor binding | GRM5, GRM3, GRIK5 | HSP90AA1 4295/4885RAB9A 2493/4885PDPK1 3009/4885 |
| US-20120004220-A9 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | HSP90AA1 982/4885RAB9A 3721/4885PDPK1 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.